Since the acquisition of Éclat, we have implemented a balanced business model allowing Flamel to commercialize niche branded (Bloxiverz®® and Vazculep®) and generic pharmaceutical products in the U.S. and other countries as appropriate, and blend novel, high-value internally developed products with our drug delivery and capabilities. Flamel’s new model allows us now to select, develop, seek approval for, and commercialize niche branded products mainly in the U.S. and most of the opportunities are self-funded. By adopting this revised strategy, the Company makes itself less dependent on the often changing strategies of partners in the future. Nevertheless, Flamel is still exploring development, supply and licensing opportunities for either its drug delivery platforms or its proprietary products with carefully selected third parties, but, unlike our historical operations, will not be dependent completely on those partnerships to create revenue and profit opportunities.
Show more
Type
Public
HQ
Vénissieux, FR
Founded
1990
Size (employees)
165 (est)+52%
Website
flamel.com
Flamel Technologies was founded in 1990 and is headquartered in Vénissieux, FR
Report incorrect company information

Flamel Technologies Office Locations

Flamel Technologies has an office in Vénissieux
Show all (1)
Report incorrect company information

Flamel Technologies Financials and Metrics

Flamel Technologies Financials

Flamel Technologies's revenue was reported to be $173.25 m in FY, 2017
USD

Revenue (FY, 2017)

173.2 m

Net income (FY, 2017)

68.3 m

EBIT (FY, 2017)

89.5 m

Market capitalization (18-Nov-2016)

432.2 m

Closing share price (18-Nov-2016)

10.8

Cash (31-Dec-2017)

16.6 m

EV

415.8 m
Flamel Technologies's current market capitalization is $432.2 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

173.2 m

General and administrative expense

21.7 m44.2 b58.9 m

R&D expense

25.6 m34.6 b33.4 m

Operating expense total

47.3 m78.8 b83.7 m
Quarterly
USDQ1, 2016Q2, 2016

General and administrative expense

9.5 m11.3 m

R&D expense

5.4 m7.6 m

Operating expense total

14.8 m18.9 m

EBIT

5.5 m(11.5 m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

65.1 m39.2 m16.6 m

Accounts Receivable

17.8 m14.8 m

Inventories

3.3 m6.2 m

Current Assets

166.3 m181.2 m124 m
Quarterly
USDQ1, 2016Q2, 2016

Cash

37.9 m23.9 m

Accounts Receivable

4.9 m9.5 m

Inventories

5.3 m3.6 m

Current Assets

180.5 m177.6 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

40.7 m(41.3 m)68.3 m

Depreciation and Amortization

13.1 m14.5 m4.9 m

Inventories

1.8 m(2.9 m)

Cash From Operating Activities

84.3 m18.9 m16.7 m
Quarterly
USDQ1, 2016Q2, 2016

Net Income

(6.4 m)(20 m)

Depreciation and Amortization

3.8 m

Inventories

1.2 m3.6 m

Accounts Payable

7 m
USDY, 2017

EV/EBIT

4.6 x

EV/CFO

25 x

Revenue/Employee

1.3 m

Financial Leverage

3 x
Show all financial metrics
Report incorrect company information